FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2749 June 28, 2007 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Hendeles, L.

To the Editor: In response to the review article by Hendeles et al. about the withdrawal of albuterol inhalers containing chlorofluorocarbon (CFC) propellants (March 29 issue),¹ although we all agree that the eventual elimination of CFC use is an important step for the planet, it has led to serious problems for uninsured and underinsured patients with airways disease. Albuterol metered-dose inhalers containing a hydrofluoroalkane (HFA) propellant, being branded, cost two to three times as much as albuterol inhalers containing a generic CFC, adding perhaps $25 monthly to a patient's medication costs.² Many patients have turned to less expensive over-the-counter alternatives . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.